{"Title": "Assessment of the drug interaction potential and single- and repeat-dose pharmacokinetics of the BRAF inhibitor dabrafenib", "Year": 2015, "Source": "J. Clin. Pharmacol.", "Volume": "55", "Issue": 4, "Art.No": null, "PageStart": 392, "PageEnd": 400, "CitedBy": 21, "DOI": "10.1002/jcph.437", "Link": "https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84924409272&origin=inward", "Abstract": "\u00a9 2014, The American College of Clinical Pharmacology.The induction of CYP2C9 by dabrafenib using S-warfarin as a probe and the effects of a CYP3A inhibitor (ketoconazole) and a CYP2C8 inhibitor (gemfibrozil) on dabrafenib pharmacokinetics were evaluated in patients with BRAF V600 mutation-positive tumors. Dabrafenib single- and repeat-dose pharmacokinetics were also evaluated. S-warfarin AUC0-- decreased 37% and Cmax increased 18% with dabrafenib. Dabrafenib AUC0-\u03c4 and Cmax increased 71% and 33%, respectively, with ketoconazole. Hydroxy- and desmethyl-dabrafenib AUC0-\u03c4 increased 82% and 68%, respectively, and AUC for carboxy-dabrafenib decreased 16%. Dabrafenib AUC0-\u03c4 increased 47%, with no change in Cmax, after gemfibrozil co-administration. Gemfibrozil did not affect systemic exposure to dabrafenib metabolites. Single- and repeat-dose dabrafenib pharmacokinetics were consistent with previous reports. All cohorts used the commercial capsules. More-frequent monitoring of international normalized ratios is recommended in patients receiving warfarin during initiation or discontinuation of dabrafenib. Substitution of strong inhibitors or strong inducers of CYP3A or CYP2C8 is recommended during treatment with dabrafenib.", "AuthorKeywords": ["CYP2C8", "CYP2C9", "CYP3A", "dabrafenib", "drug interaction"], "IndexKeywords": ["Anticoagulants", "Cytochrome P-450 CYP2C8 Inhibitors", "Cytochrome P-450 CYP3A Inhibitors", "Drug Interactions", "Female", "Gemfibrozil", "Humans", "Imidazoles", "Ketoconazole", "Male", "Middle Aged", "Oximes", "Protein Kinase Inhibitors", "Proto-Oncogene Proteins B-raf", "Warfarin"], "DocumentType": "Journal", "PublicationStage": null, "OpenAccess": 0, "EID": "2-s2.0-84924409272", "SubjectAreas": [["Pharmacology", "PHAR", "3004"], ["Pharmacology (medical)", "MEDI", "2736"]], "AuthorData": {"6603648361": {"Name": "Suttle A.B.", "AuthorID": "6603648361", "AffiliationID": "115044249", "AffiliationName": "Provonix LLC, Mullica Hill"}, "55617853000": {"Name": "Ouellet D.", "AuthorID": "55617853000", "AffiliationID": "60097308", "AffiliationName": "GlaxoSmithKline, Research Triangle Park"}, "57197226279": {"Name": "Carson S.W.", "AuthorID": "57197226279", "AffiliationID": "60097308", "AffiliationName": "GlaxoSmithKline, Research Triangle Park"}, "55200307600": {"Name": "Grossmann K.F.", "AuthorID": "55200307600", "AffiliationID": "60116851", "AffiliationName": "Salix Pharmaceuticals"}, "7405876997": {"Name": "Sharma S.", "AuthorID": "7405876997", "AffiliationID": "60116851", "AffiliationName": "Salix Pharmaceuticals"}, "55895007100": {"Name": "Richards-Peterson L.E.", "AuthorID": "55895007100", "AffiliationID": "60136293, 60025488", "AffiliationName": "Huntsman Cancer Institute, University of Utah"}, "54893881800": {"Name": "Aktan G.", "AuthorID": "54893881800", "AffiliationID": "60136293, 60025488", "AffiliationName": "Huntsman Cancer Institute, University of Utah"}, "7402801321": {"Name": "Gordon M.S.", "AuthorID": "7402801321", "AffiliationID": "60097308", "AffiliationName": "GlaxoSmithKline, Collegeville"}, "7005502523": {"Name": "Lorusso P.M.", "AuthorID": "7005502523", "AffiliationID": "110116777", "AffiliationName": "Pinnacle Oncology Hematology"}, "15843528200": {"Name": "Infante J.R.", "AuthorID": "15843528200", "AffiliationID": "60009408, 60033199", "AffiliationName": "Karmanos Cancer Institute, Wayne State University"}, "6602805226": {"Name": "Kendra K.", "AuthorID": "6602805226", "AffiliationID": "60015281", "AffiliationName": "Sarah Cannon Research Institute/Tennessee Oncology, PLLC"}, "57202897196": {"Name": "Patel M.", "AuthorID": "57202897196", "AffiliationID": "60003500", "AffiliationName": "Ohio State University"}, "24776810800": {"Name": "Pant S.", "AuthorID": "24776810800", "AffiliationID": "115043916", "AffiliationName": "Sarah Cannon Research Institute, Florida Cancer Specialists"}, "6603300234": {"Name": "Arkenau H.T.", "AuthorID": "6603300234", "AffiliationID": "60030931", "AffiliationName": "Sarah Cannon Research Institute, University of Oklahoma"}, "7103103337": {"Name": "Middleton M.R.", "AuthorID": "7103103337", "AffiliationID": "60022148", "AffiliationName": "Sarah Cannon Research Institute, United Kingdom and University College London"}, "55190190000": {"Name": "Blackman S.C.", "AuthorID": "55190190000", "AffiliationID": "60002634", "AffiliationName": "Department of Oncology, National Institute for Health Research, Biomedical Research Centre"}, "8593933600": {"Name": "Botbyl J.", "AuthorID": "8593933600", "AffiliationID": "114886526", "AffiliationName": "Juno Therapeutics, Seattle"}}}